C
Curon Biopharma
Develops innovative cancer immunotherapies, with several promising treatments in clinical stages
About Curon Biopharma
Curon Biopharma operates as a clinical-stage biopharmaceutical company with a focus on developing treatments for cancer. Founded in 2018, the company was incubated by the healthcare-focused investment firm 6 Dimensions Capital. Its establishment included a significant $150 million Series A financing round from investors such as 6 Dimensions Capital, Boyu Capital, and Temasek. Headquartered in Shanghai, China, Curon also maintains operations in Australia and Hong Kong.
The company's business model centers on the research, development, and monetization of a pipeline of immuno-oncology therapies. Revenue is generated through strategic partnerships and asset acquisitions by larger pharmaceutical companies. A notable achievement was the agreement with Merck for the global rights to Curon's lead asset, CN201. This deal involved a substantial upfront payment of $700 million, with the potential for an additional $600 million in milestone payments tied to development and regulatory approvals. Zhihong Chen serves as the company's president and CEO, with Dr. Paul H. Song appointed as Chief Scientific Officer in 2018. Dr. Song contributes over 25 years of experience in pharmaceutical research and development, including roles at Eli Lilly and Samsung Bioepis.
Curon's product pipeline features multiple candidates, including bispecific antibodies and antibody-drug conjugates. The lead candidate, CN201, is a bispecific antibody designed to target and eliminate B-cells by engaging T-cells. It works by targeting both the CD3 protein on T-cells and the CD19 protein on B-cells. This mechanism has shown potential in treating B-cell malignancies and autoimmune diseases. CN201 has been evaluated in clinical trials for conditions such as relapsed or refractory non-Hodgkin's lymphoma (NHL) and B-cell acute lymphocytic leukemia (ALL). Preliminary data from these trials indicated that the therapy was well-tolerated and showed activity in reducing B-cell populations in patients.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jul 2018 | $150M | $600M | Temasek · Boyu Capital · 6 Dimensions Capital | — |
Growth signals
Latest recorded traffic for Curon Biopharma is 700 monthly website visits, up 66.7% over the last three months. Curon Biopharma's team declined 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Curon Biopharma in the Huangpu ecosystem
The Curon Biopharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Temasek
Boyu Capital
6 Dimensions Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Curon Biopharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Curon Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







